IPUD
IPUD – An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in diuretic resistant heart failure patients.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IPUD project word cloud
Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.
Project "IPUD" data sheet
The following table provides information about the project.
| Coordinator |
PARAGATE MEDICAL LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Project website | http://paragate-medical.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2018-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PARAGATE MEDICAL LTD | IL (NAZARETH) | coordinator | 50˙000.00 |
Map
Project objective
Fluid overload (congestion) is a classic clinical symptom and cause of distress among heart failure (HF) and chronic kidney disease (CKD) patients. Diuretics are currently the gold standard treatment but of the 26 million heart failure patients annually around the world, over one third are diuretic resistant. Current solutions for fluid overload in diuretic resistant patients such as IV diuresis, ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence.
IPUD improves the clinical condition of fluid overloaded patients by continuously removing extracellular fluids with a unique implantable peritoneal ultrafiltration device, operating non-aggressively and independently from the kidneys’ function. IPUD is minimally invasive (laparoscopic approach) and the flat absorption device interfaces with the intraperitoneal membrane and applies a hydrostatic pressure gradient. It then continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. The device has a projected service life of 3 years and recharging the device has been made simple for the patients via wireless charging, needed on a weekly basis.
The global congestive heart failure treatment device market is worth almost $6 billion and is poised to grow at a CAGR of around 6.4% over the next decade to reach approximately $17.8 billion by 2025. IPUD will be sold directly to hospitals and clinics for approximately €30,000 through collaborations with the major distributors of heart failure devices.
Our senior team has over 50 years’ experience in the cardiology and medical device sectors combined with extensive academic education. We have raised €1 million in funding. Our full-time staff headcount is 4. Partnerships have been secured with several manufacturing subcontractors, including Sensirion in Switzerland, Inomec in Israel and Bossert Kast in Germany.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.